The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) to Bayer Healthcare Pharmaceuticals Inc., a subsidiary of the global pharmaceutical company Bayer AG. The BPA, valued at $45 million, is for the supply of two pharmaceutical products: Xofigo (radium Ra 223 dichloride) for the treatment of prostate cancer, and Adempas (riociguat) for the treatment of pulmonary arterial hypertension.
As the prime contractor, Bayer Healthcare Pharmaceuticals Inc. will provide these critical medications to the VA through its Federal Supply Schedule (FSS) contract with the parent company Bayer AG Pharmaceuticals Division. The contract supports the VA's efforts to deliver comprehensive healthcare services to veterans, particularly through the Veterans Integrated Service Network 22 facility in Long Beach, California. The BPA does not utilize any set-aside designations and has an ultimate completion date of October 5, 2025.
Generated 12/13/24, 9:05 AM